Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (41-50 of 146) with videos related to

Pageof 15
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 23, 2009
[Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies]Akito Hata, Shigeki Nanjo, Kyoko Otsuka, et al.
Internal Medicine (Tokyo, Japan)|March 10, 2015
Multiple primary malignancies in patients with non-small cell lung cancerShiro Fujita, Katsuhiro Masago, Jumpei Takeshita, et al.
Lung Cancer (Amsterdam, Netherlands)|October 12, 2014
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancerToshihiko Kaneda, Akito Hata, Hiromi Tomioka, et al.
Oncotarget|March 24, 2018
CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cellsAkito Nakamura, Daisuke Nakata, Yuichi Kakoi, et al.
Advances in Therapy|September 16, 2023
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall PhaseNaoki Inui, Yukihiro Toi, Yasuto Yoneshima, et al.
Clinical Lung Cancer|September 11, 2018
Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib StudyHiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, et al.
Oncotarget|July 3, 2018
Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancerAkito Hata, Daijiro Harada, Chiyuki Okuda, et al.
Molecular and Clinical Oncology|March 24, 2015
Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancerKatsuhiro Masago, Daichi Fujimoto, Shiro Fujita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinomaAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Molecular Cancer Therapeutics|February 1, 2017
<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung CancerShigeki Nanjo, Sachiko Arai, Wei Wang, et al.
Pageof 15

Showing results (41-50 of 146) with videos related to

Sort By:
Pageof 15
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 23, 2009
[Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies]Akito Hata, Shigeki Nanjo, Kyoko Otsuka, et al.
Internal Medicine (Tokyo, Japan)|March 10, 2015
Multiple primary malignancies in patients with non-small cell lung cancerShiro Fujita, Katsuhiro Masago, Jumpei Takeshita, et al.
Lung Cancer (Amsterdam, Netherlands)|October 12, 2014
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancerToshihiko Kaneda, Akito Hata, Hiromi Tomioka, et al.
Oncotarget|March 24, 2018
CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cellsAkito Nakamura, Daisuke Nakata, Yuichi Kakoi, et al.
Advances in Therapy|September 16, 2023
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall PhaseNaoki Inui, Yukihiro Toi, Yasuto Yoneshima, et al.
Clinical Lung Cancer|September 11, 2018
Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib StudyHiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, et al.
Oncotarget|July 3, 2018
Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancerAkito Hata, Daijiro Harada, Chiyuki Okuda, et al.
Molecular and Clinical Oncology|March 24, 2015
Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancerKatsuhiro Masago, Daichi Fujimoto, Shiro Fujita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinomaAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Molecular Cancer Therapeutics|February 1, 2017
<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i>-mutant Lung CancerShigeki Nanjo, Sachiko Arai, Wei Wang, et al.
Pageof 15